B#B.CSC.[CH3:6][C:7]1([CH3:40])[C:11](=[O:12])[N:10]([C:13]2[CH:18]=[CH:17][C:16]([C:19]([CH3:24])([CH3:23])[C:20](O)=[O:21])=[CH:15][CH:14]=2)[C:9](=[O:25])[N:8]1[CH2:26][C:27]1[CH:32]=[CH:31][N:30]=[C:29]([NH:33][C:34]2[CH:35]=[N:36][CH:37]=[CH:38][CH:39]=2)[CH:28]=1.O.[OH-].[Na+]>O1CCCC1.CO.Cl.C(OCC)(=O)C>[OH:21][CH2:20][C:19]([C:16]1[CH:17]=[CH:18][C:13]([N:10]2[C:11](=[O:12])[C:7]([CH3:40])([CH3:6])[N:8]([CH2:26][C:27]3[CH:32]=[CH:31][N:30]=[C:29]([NH:33][C:34]4[CH:35]=[N:36][CH:37]=[CH:38][CH:39]=4)[CH:28]=3)[C:9]2=[O:25])=[CH:14][CH:15]=1)([CH3:24])[CH3:23]To a solution of 0.29 mL of diborane-dimethyl sulphide (2M in tetrahydrofuran) in 5 mL of tetrahydrofuran, under argon, at room temperature, is added 0.11 g of 2-(4-{4,4-dimethyl-2,5-dioxo-3-[2-(pyridin-3-ylamino)pyridin-4-ylmethyl]imidazolidin-1-yl}-phenyl)-2-methylpropionic acid obtained in stage f) below. The reaction medium is stirred at this same temperature for one hour and concentrated under reduced pressure. The residue obtained is taken up in 10 mL of methanol and 2 mL of 1N hydrochloric acid. The solution is concentrated under reduced pressure. The residue obtained is purified by Preparative LC/MS (gradient: acetonitrile/water/TFA 0.07%). The product obtained is taken up in 10 mL of ethyl acetate, 2 mL of water and 1 mL of 1N sodium hydroxide. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure to give 0.048 g of 3-[4-(2-hydroxy-1,1-dimethylethyl)phenyl]-5,5-dimethyl-1-{[2-(pyridin-3-ylamino)-pyridin-4-yl]methyl}imidazolidine-2,4-dione, the characteristics of which are as follows:
불러오는 중…